Expand VRTX Menu
VRTX MENU

VRTX Latest Press Releases

-- June 11, 2026 --

Vertex Presents New Data on CASGEVY, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions Business Wire 2:01 AM

-- June 5, 2026 --

Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference Business Wire 12:00 PM

-- June 3, 2026 --

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 Business Wire 4:00 PM

-- June 1, 2026 --

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy Business Wire 8:00 AM

-- May 11, 2026 --

Vertex to Participate in Upcoming May Investor Conferences Business Wire 4:00 PM

-- May 6, 2026 --

Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany Business Wire 7:01 AM

-- May 4, 2026 --

Vertex Reports First Quarter 2026 Financial Results Business Wire 4:01 PM

-- April 6, 2026 --

Vertex to Announce First Quarter 2026 Financial Results on May 4th Business Wire 4:00 PM

-- April 1, 2026 --

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK and TRIKAFTA, Expanding Availability of These Medicines to ~95% of All People With CF in the United States Business Wire 7:30 AM

-- March 9, 2026 --

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Business Wire 4:02 PM

-- March 5, 2026 --

Vertex to Participate in Upcoming March Investor Conferences Business Wire 4:00 PM
Vertex to Present New Data on JOURNAVX That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures Business Wire 10:00 AM

-- February 17, 2026 --

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 Business Wire 4:00 PM

-- February 12, 2026 --

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:01 PM

-- February 2, 2026 --

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager PRNewswire 10:08 PM

-- January 29, 2026 --

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs Business Wire 7:00 AM

-- January 23, 2026 --

Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets Globe Newswire 12:56 PM
Market Data Delayed 15 Minutes